MME and heart failure: In 2017, update of the guidelines for the management of heart failure released by ACC/AHA/HFSA (American College of Cardiology Foundation/American Heart Association/Heart Failure Society of America), angiotensin receptor–neprilysin inhibitors (ARNI) (sacubitril/valsartan) and sinoatrial node modulators (ivabradine) were classified as the therapy for stage C heart failure in the evidence of level B-R, but require further high-quality randomized clinical trials to be conducted (Dixon et al., 2012; Yancy et al., 2017).